Yes, something tells me from the consistency of his posts that he is running a pay for service operation. His approach shows definite strategy. Strange though, as far as I know without wasting my time doing the due diligence, he has refrained from mentioning Oncarlytics in his line up of Imugene’s flawed/failing/not-cutting-it therapy candidates
IMU Price at posting:
1.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)